Are Options Traders Betting on a Big Move in BCRX Stock?
Investors need to pay close attention to BioCryst Pharmaceuticals stock based on the movements in the options market lately.
BioCryst Announces Departure of Dr. Helen Thackray - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the year.
BioCryst Announces Departure of Dr. Helen Thackray
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory role through the end of the ...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and ...
BioCryst Pharmaceuticals ( BCRX ) Surpasses Q2 Earnings and Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +400.00% and +9.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BioCryst ( BCRX ) Q2 Revenue Jumps 50%
BioCryst Pharmaceuticals ( NASDAQ:BCRX ) , a biotechnology company specializing in oral treatments for rare diseases, released its second quarter earnings on August 4, 2025, reporting its strongest quarterly results to date.
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
BCRX gears up for Q2 results with Orladeyo growth in focus, but 2025 EPS forecasts dip as investors eye pipeline progress.
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025.
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals ( BCRX ) Reports Next Week: Wall Street Expects Earnings Growth
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst to Report Second Quarter 2025 Financial Results on August 4
RESEARCH TRIANGLE PARK, N.C., July 21, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company will report its second quarter 2025 financial results on Monday, August 4, 2025.
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline - Clearside Biomedical ( NASDAQ:CLSD )
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD -
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 09, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company will present new findings from patient-focused research highlighting the burden of current treatments for HAE on pediatric patients under the age of 12 and their ...
Is BioCryst Pharmaceuticals ( BCRX ) Outperforming Other Medical Stocks This Year?
Here is how BioCryst Pharmaceuticals (BCRX) and Cardinal Health (CAH) have performed compared to their sector so far this year.
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced the appointment of Babar Ghias as chief financial officer ( CFO ) and head of corporate development.
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development
RESEARCH TRIANGLE PARK, N.C., July 07, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced the appointment of Babar Ghias as chief financial officer ( CFO ) and head of corporate development.
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 57,000 ...
Select Medical Expands Presence in Tennessee With Ballad Health Deal
SEM partners with Ballad Health to relocate and expand its Tri-Cities critical illness recovery hospital, boosting care access in Tennessee by being able to treat more patients grappling with serious illnesses.
BioCryst Just Ditched Its Europe Business - Here's Why Investors Are Cheering - BioCryst Pharma ( NASDAQ:BCRX )
BioCryst to retire $249 million Pharmakon debt, saving about $70 million in future interest. The company expects $700 million in cash and zero-term debt by the end of 2027, up $400 million from the prior forecast. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this ...
BioCryst Announces Sale of European ORLADEYO® ( berotralstat ) Business to Neopharmed Gentili for up to $264 Million - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., June 27, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that it has entered into a definitive agreement to sell its European ORLADEYO® ( berotralstat ) business to Neopharmed Gentili for up to $264 million.
BioCryst Announces Sale of European ORLADEYO® ( berotralstat ) Business to Neopharmed Gentili for up to $264 Million
-Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future ...
BioCryst ( BCRX ) Upgraded to Strong Buy: What Does It Mean for the Stock?
BioCryst (BCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility
INSW, ASR, BCRX, ASC and RRGB top the list of highly efficient stocks poised for gains amid market volatility.
New Strong Buy Stocks for June 25th
BILI, AEM, EVR, VEEV and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on June 25, 2025.
Are Medical Stocks Lagging Acurx Pharmaceuticals ( ACXP ) This Year?
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® ( berotralstat ) Across all Ages at EAACI
-Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety ...
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® ( berotralstat ) Across all Ages at EAACI - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., June 16, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced new data on the long-term efficacy and safety of ORLADEYO® ( berotralstat ) for the prophylactic treatment of hereditary angioedema ( HAE ) in patients across all age groups.
ORLADEYO® ( berotralstat ) Approved in Colombia
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the National Institute of Drug and Food Surveillance ( INVIMA ) in Colombia has granted approval for oral, once-daily ORLADEYO® ( berotralstat ) for the ...
ORLADEYO® ( berotralstat ) Approved in Colombia - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc.
United Therapeutics ( UTHR ) Soars 3.5%: Is Further Upside Left in the Stock?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries
ORLADEYO® ( berotralstat ) now reimbursed in the Netherlands ORLADEYO® ( berotralstat ) now reimbursed in the Netherlands ...
BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., June 06, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® ( berotralstat ) has been approved for the routine prevention of hereditary angioedema ( HAE ...
BioCryst Pharmaceuticals ( BCRX ) is a Great Momentum Stock: Should You Buy?
Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
New Strong Buy Stocks for June 4th
BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units ( RSUs ) covering an aggregate of 47,250 ...
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc.
BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., June 02, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that new data on oral, once-daily ORLADEYO® ( berotralstat ) for the prophylactic treatment of hereditary angioedema ( HAE ) will be presented at the European Academy ...
BioCryst Highlights Real-world Data Showing ORLADEYO® ( berotralstat ) Consistently Reduces HAE Attacks Across All Ages
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life ...
Is Bayer ( BAYRY ) Outperforming Other Medical Stocks This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
BioCryst to Present at Upcoming Investor Conferences - BioCryst Pharma ( NASDAQ:BCRX )
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the company plans to present at the following conferences: Jefferies Global Healthcare Conference in New York on Wednesday, June 4, 2025, at 4:55 p.m. ET.
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., May 27, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced that the company plans to present at the following conferences: ...
Wall Street Analysts Believe BioCryst ( BCRX ) Could Rally 55.81%: Here's is How to Trade
The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® ( berotralstat )
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. ( Nasdaq: BCRX ) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® ( berotralstat ) in adolescents and people with severe HAE showing significant and sustained ...
BioCryst Announces FDA Acceptance of NDA for ORLADEYO® ( berotralstat ) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years - BioCryst Pharma ( NASDAQ:BCRX )
-ORLADEYO would be the first targeted oral prophylactic therapy for patients with HAE under the age of 12, if approved- RESEARCH TRIANGLE PARK, N.C., May 14, 2025 ( GLOBE NEWSWIRE ) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that the U.S.
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in ...
Best Momentum Stocks to Buy for May 9th
BCRX, WYY and RMBS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2025.
New Strong Buy Stocks for May 9th
CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.
